Now ethical clearance is on its way and we dose first human. But the progression of phase 1 in line with Walter Reed results 1 month later puts the company in poll position to access the 20 million in non dilutive funding phase 2. Good news flow ahead setting up the company
Ann: NYR Completes Safety Studies Ahead of Phase I Clinical Trial, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.82M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 35.0¢ | 31.0¢ | $188.4K | 569.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 30034 | 2 |
View Market Depth
| Last trade - 15.33pm 22/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |